Abstract:

 Objective To evaluate the effectiveness of intravitreal injection of conbercept (IVC) for retinopathy of prematurity (ROP). Design Retrospective case series. Participants 24 patients (47 eyes) of ROP including threshold lesions or pre-threshold lesions of type I in 33 eyes and aggressive posterior ROP (AP-ROP) in 14 eyes had received IVC in Xiamen Children’s Hospital from January to December 2017. Methods All patients were treated with IVC 0.03 ml. Follow-up examinations were performed at 1, 2, 4, 6, 10, 14, 18, 24 weeks after treatment. Effective treatment included disappearance of additional lesions, reduction of vasodilation, crest regression and vascularization of peripheral non-vascularized areas. Main Outcome Measures Numbers of eyes with effectiveness or recurrence. Results All the eyes had received the IVC. 39 eyes were cured for single injection. 4 eyes had received twice injections. 4 eyes had required additional laser photocogulation. 1 eye had received vitrectomy. All the treatments were effective, and no recurrence was found in the follow-up examinations. During the follow-up, local punctiform effusion which was along with the retinal blood vessel was observed in 2 eyes following the first examination. No notable ocular and systemic complications related to the IVC injections were observed. Conclusions IVC is effective in the treatment of ROP, but the safety need to be evaluated for a long time. (Ophthalmol CHN, 2019, 28: 52-55)

Key words: retinopathy of prematurity, conbercept